Tag:

Medivation

Latest Headlines

Latest Headlines

Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study

When Medivation bought out the rights to CureTech's pidilizumab, it trumpeted its entry into checkpoint inhibition with a drug that aimed right at PD-1, unleashing a T cell attack on cancer. Except that Medivation recently concluded that the drug doesn't work that way after all--and now the FDA has red-flagged a pivotal study of the drug, halting the trial through a partial clinical hold while Medivation takes another stab at explaining the mechanism of action.

NIH urged to 'break taboo' against using its power to bypass drug patents

The National Institutes of Health (NIH) has said that it would take "extraordinary" circumstances for the agency to address rising drug prices, even as skyrocketing costs draw criticism from patients, payers and the public. But two organizations think that it's about time for the NIH to act. And they're not mincing words with their request.

Astellas, Medivation report successful enzalutamide mCRPC PhII data in Lancet

The U.S. arm of Tokyo-based Astellas Pharma and U.S.-listed Medivation said enzalutamide met its primary endpoint in a Phase II study to treat metastatic castration-resistant prostate cancer (mCRPC).

NICE backs Astellas' Xtandi in pre-chemo patients, but J&J's Zytiga isn't so lucky

Astellas and Medivation's prostate cancer med Xtandi has been coming up strong behind Zytiga from Johnson & Johnson ever since hitting the market. And now, it's getting a boost in the U.K. that should help it gain more ground against its rival.

Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitor

Medivation made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too. 

Watch out, AZ: Medivation sees 'best-in-class' prospects for its new PARP inhibitor

Medivation made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too.

Medivation snaps up BioMarin's late-stage breast cancer med in $410M-plus deal

Lots of companies are working to bulk up in the cancer field--but not BioMarin. Buckling down on rare diseases, the company is out-licensing its Phase III PARP inhibitor to Medivation for $410 million up front, with another $160 million in milestones.

UPDATED: BioMarin sells its PhIII cancer drug to Medivation for $570M

Setting its sights squarely on a future focused on rare diseases, BioMarin has opted to out-license its Phase III PARP inhibitor to Medivation for $410 million upfront with another $160 million in milestones.

Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use

Astellas and Medivation haven't been marketing Xtandi much for the pre-chemotherapy indication in prostate cancer it won last fall. Begun two months ago, the direct-to-consumer efforts--mostly in print--has appeared in journals such as  Patient Resourc e; it also includes some direct relationship marketing.

Medivation buys into PD-1, picking up where Teva left off

The prostate cancer experts at Medivation are getting into the hot field of checkpoint inhibitors for cancer, agreeing to pay Israel's CureTech as much as $335 million for the full rights to a promising Phase II asset.